PRLD News and Press, Prelude Therapeutics Incorporated From 03/16/21

– Dose Escalation Portion of Phase 1 Trial of PRT543 Complete; Additional Expansion Cohorts Set to Initiate Early in the Second Quarter – – Clinical Data Readouts Expected in 2H21 for Lead PRMT5 Inhibitors PRT543 and PRT811 – – Phase 1 ...

WILMINGTON, Del., March 03, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (“Prelude”, “the Company”, “we”, “our”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that members of its management team wil...

WILMINGTON, Del., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the closing of its upsized public offering of 2,583,334 shares of its v...

Prelude Therapeutics (PRLD) has priced upsized public offering of ~2.21M shares (from 1.75M) of its voting common stock and 291,666 of non-voting common stock, each at $60.00/share, for expected gross proceeds of $150M.Underwriters' over-allotment is an additional 375K shares of voting common...

WILMINGTON, Del., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Wilmington, DE – January 7, 2021 – Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the pricing of its ups...

Prelude Therapeutics (PRLD)  commenced a public offering of 1.75M shares; underwriters granted 30-day option to purchase up to an additional 262.5K shares.Actual size, offer terms not yet disclosed. For further details see: Prelude Therapeutics readies public offering

WILMINGTON, Del., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (“Prelude” or “the Company”) (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that it has commenced a public offering of 1,750,000 shares of its comm...

In my 2020 outlook, which was pre-coronavirus, I argued the case for buying small and microcap medical stocks that were priced for "non-success". This approach worked in 2020. My 2020 themes were gene therapy, targeted oncologics, and less invasive surgery. For 2021, I add SARS CoV-2 ...

Prelude Therapeutics (PRLD): Q3 GAAP EPS of -$5.25.Cash and cash equivalents of $234.8M.Press Release. For further details see: Prelude Therapeutics reports Q3 results

- Completed I nitial P ublic O ffering of C ommon S tock, R aising G ross P roceeds of ~$ 181.9M - - Partial Response Confirmed in Glioblastoma Multiforme Patient in Phase 1 Trial of PRT811 -...